Blood Test That Detects 17 Types of Cancer Shows Strong Results in Large Prospective Study

A large prospective study has demonstrated the effectiveness of a new blood test capable of detecting 17 different types of cancer, according to research highlighted by the Mayo Clinic News Network in September 2026.

The multicancer detection test works by analyzing biological signals in the blood, including cell-free DNA, to identify cancer before symptoms appear. Early detection is one of the most important factors in cancer survival rates.

The 17 cancer types covered by the test include several that are notoriously difficult to catch early, such as pancreatic cancer and ovarian cancer. These cancers often go undetected until they have reached advanced stages, when treatment options are more limited.

Multicancer detection tests represent a shift in cancer screening strategy. Traditional screening methods, such as mammograms and colonoscopies, target one cancer type at a time. A single blood test that screens for multiple cancers simultaneously could make early detection more accessible and efficient.

The prospective study design, which follows participants forward in time rather than looking backward at existing data, provides stronger evidence for the test's real-world effectiveness.

Researchers and clinicians are working to determine how these tests will be integrated into standard preventive care. Questions remain about follow-up protocols when a test returns a positive signal, including which imaging or biopsy procedures should be used to confirm a diagnosis.

The FDA has been reviewing multicancer detection tests, and several companies are working toward regulatory approval for their products.